Tag - TSHA

Markets

WB starts Taysha Gene Therapies at OP; fair value estimate $46

William Blair launched coverage of Taysha Gene Therapies (NASDAQ:TSHA) with an “outperform” rating and fair value estimate of $46. The stock closed at $26.66 on Feb. 23. Taysha is focused on developing and...

February 23, 2021

Developments

Taysha gets FDA rare pediatric and orphan drug designations for epilepsy

Taysha Gene Therapies’ (NASDAQ:TSHA) TSHA-103 received FDA rare pediatric and orphan drug designations for the treatment of SLC6A1-related epilepsy. SLC6A1-related epilepsy is caused by the loss of function of one copy...

December 3, 2020

Developments

Taysha gets FDA rare pediatric and orphan drug designations for Leigh syndrome

Taysha Gene Therapies (NASDAQ:TSHA) received FDA rare pediatric and orphan drug designations for TSHA-104 for the treatment of SURF1-associated Leigh syndrome. Leigh syndrome is a severe neurological disorder that...

October 27, 2020

Developments

Taysha gets FDA rare pediatric and orphan drug designations for Rett syndrome

Taysha Gene Therapies (NASDAQ:TSHA) received FDA rare pediatric and orphan drug designations for TSHA-102 for the treatment of Rett syndrome. Rett syndrome is a genetic neurodevelopmental disorder characterized by...

October 14, 2020

Tag - TSHA

WB starts Taysha Gene Therapies at OP; fair value estimate $46

Taysha gets FDA rare pediatric and orphan drug designations for epilepsy

Taysha gets FDA rare pediatric and orphan drug designations for Leigh syndrome

Taysha gets FDA rare pediatric and orphan drug designations for Rett syndrome

General

More